GABA_A/Benzodiazepine Receptor Complex in the Dorsal Hippocampus Mediates the Effects of Chrysin on Anxiety-Like Behaviour in Female Rats

Juan Francisco Rodríguez-Landa1,2*, Fabiola Hernández-López3, Lucia Martínez-Mota4, Damiana Scuteri5,6, Blandina Bernal-Morales1,2 and Eduardo Rivadeneyra-Domínguez2

1 Laboratorio de Neurofarmacología, Instituto de Neuroetología, Universidad Veracruzana, Xalapa, Mexico, 2 Facultad de Química Farmacéutica Biológica, Universidad Veracruzana, Xalapa, Mexico, 3 Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No. 66, Xalapa, Mexico, 4 Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico, 5 Pharmacotechnology Documentation and Transfer Unit, Section of Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy, 6 Regional Center for Serious Brain Injuries, S. Anna Institute, Crotone, Italy

Systemic injections of the flavonoid chrysin (5,7-dihydroxyflavone) exert anxiolytic-like effects in ovariectomised and cycling female rats through actions on gamma-aminobutyric acid-A (GABA_A) receptors; however, it is unknown if chrysin directly acts on brain structures that are involved in regulating emotional processes, such as the hippocampus. The present study evaluated the effects of intrahippocampal microinjections of 0.25, 0.5, and 1 µg of chrysin on anxiety-like behaviour in the elevated plus maze (EPM) and locomotor activity test (LAT) in female rats in proestrus and dioestrus. Similar doses of the neurosteroid allopregnanolone were used as a reference GABAergic anxiolytic drug. The participation of the GABA_A/benzodiazepine receptor complex was evaluated by administering the antagonists picrotoxin, bicuculline and flumazenil. In proestrus, 0.5 and 1 µg of chrysin and allopregnanolone induced anxiogenic-like behaviour. In dioestrus, chrysin, and allopregnanolone (0.5 µg) induced anxiolytic-like effects. Picrotoxin, bicuculline and flumazenil prevented the effects of chrysin and allopregnanolone in both proestrus and dioestrus. None of the treatments significantly affected locomotor activity. These results indicate that the GABA_A/benzodiazepine receptor complex in the dorsal hippocampus regulates the effects of chrysin on anxiety-like behaviour, similar to the actions of allopregnanolone. The divergent effects of treatments across the oestrous cycle phases suggest complex interactions between GABA_A receptors and compounds with an anxiolytic potential.

Keywords: allopregnanolone, anxiety, flavonoid, GABA_A receptor, ovarian cycle
INTRODUCTION

Some anxiety disorders affect a higher percentage of women than men worldwide (Piggott et al., 2019), which have been associated with hormonal, biochemical, psychological and sociocultural factors (Velasco et al., 2019). Fluctuations in plasma and brain concentrations of oestradiol, progesterone, and some of their metabolites during the ovarian cycle are related to females’ higher vulnerability to stressors that may trigger anxiety (Rodríguez-Landa et al., 2015; Stanikova et al., 2019). At the preclinical level, anxiety-like behaviour is higher during metoestrus-dioestrus, characterised by low concentrations of steroid hormones than prooestrus-oestrus which, in contrast, presents high hormonal concentrations (Marcondes et al., 2001). This naturally occurring anxiety-like behaviour prompted the evaluation of substances that relieve anxiety associated with metoestrus-dioestrus (Ravenelle et al., 2018; García-Ríos et al., 2019; Rodríguez-Landa et al., 2021), which is a physiological state similar to the premenstrual period in women (Lovick, 2008). In this way, some flavonoids exert anxiolytic-like effects in rodents. The systemic administration of chrysin (5,7-dihydroxylavone) produces anxiolytic-like effects in male rats (Salgueiro et al., 1997; Zanoli et al., 2000), ovariectomised and cycling female rats (Rodríguez-Landa et al., 2019, 2021). Such effects are blocked by gamma-aminobutyric acid-A (GABA_A) receptor complex antagonists, suggesting that chrysin shares similar mechanisms of action with anxiolytic drugs and neurosteroids (Crocetti and Guerrini, 2020). This flavonoid exerts neurochemical and neurotrophic effects in brain structures involved in the neurobiology of anxiety and depression, such as the prefrontal cortex and limbic cortex (Filho et al., 2015; Germán-Ponciano et al., 2021).

The GABA_A/benzodiazepine receptor complex is widely distributed in brain structures involved in emotional processing (Pirker et al., 2000; Engin and Treit, 2007b; Albrecht et al., 2021) such as the hippocampus, which is a target of anxiolytic drugs (Farajdokht et al., 2020). Intrahippocampal microinjections of GABAergic compounds produce anxiolytic- and antidepressant-like effects that are blocked by GABA_A receptor antagonists (Nin et al., 2008; Rezvanfard et al., 2009; Rodríguez-Landa et al., 2009; Farajdokht et al., 2020). However, it is unknown if the hippocampus modulates anxiolytic-like effects produced by the flavonoid chrysin in cycling female rats via GABAergic actions. Previously, we have demonstrated that specific doses of picrotoxin, bicuculline, and flumazenil (all injected i.p.) antagonise the anxiolytic-like effects of GABAergic compounds without exerting intrinsic activity (Rodríguez-Landa et al., 2013, 2019); which permits their use as a pharmacological tool to explore the potential mechanism of action of GABAergic compounds with anxiolytic effects. Therefore, we extend our knowledge of the participation of the hippocampus, where the Cornus Ammonis 1 (CA1) area plays a critical role in anxiety-like behaviour through ligands that act on the GABA_A receptor (Rezayat et al., 2005; Jimenez et al., 2018).

We hypothesised that a microinjection of chrysin in the CA1 area of the dorsal hippocampus reduces anxiety-like behaviour in dioestrus through the GABA_A/benzodiazepine receptor complex.
Experimental Groups and Treatments

Experiment 1. Effects of Chrysin on Anxiety-Like Behaviour

Female rats were assigned to 14 independent groups (N = 112 rats): seven groups in prooestrus and seven groups in dioestrus. For each phase group, rats received a single intra-hippocampal microinjection as follows: vehicle (35% 2-hydroxypropyl-γ-cyclodextrin solution), chrysin (0.25, 0.5, and 1 μg, respectively) and allopregnanolone (0.25, 0.5, and 1 μg, respectively). All rats were evaluated using the elevated plus maze (EPM) and locomotor activity test (LAT) as previously reported (Rodríguez-Landa et al., 2009). The dosage was based on a previous study, in which the intrahippocampal administration of 0.2 μg of allopregnanolone produced anxiolytic-like effects in the open-field test (Martín-García and Pallarés, 2005). In the present study, a wider dose range was assessed to identify possible anxiolytic-like effects in two paradigms, as illustrated in Figure 1A.

Experiment 2. Influence of GABA<sub>A</sub> Antagonists on Chrysin-Induced Anxiolytic Activity

To evaluate the role of GABA<sub>A</sub>/benzodiazepine receptor complex in the anxiolytic-like effect of chrysin and allopregnanolone, the rats were assigned to 12 independent groups (N = 96): six groups in proestrus and six groups in dioestrus. For each oestrous phase, the animals received single i.p. injections of picrotoxin (1 mg/kg), bicuculline (1 mg/kg) or flumazenil (5 mg/kg), and 30 min later, they were microinjected intra-hippocampus with chrysin or allopregnanolone at the effective dose (0.5 μg/rat) identified in experiment 1. To reduce the number of animals according to the 3R principles (Russell et al., 2005), the proestrus and dioestrus rat groups that were microinjected with the anxiolytic dose of chrysin or allopregnanolone (0.5 μg) were taken from Experiment 1 and used for statistical analysis. All rats were evaluated in the EPM and LAT as illustrated in Figure 1B. Antagonist schedules were based on a previous study in which such doses (all of them i.p. injected) antagonised anxiolytic-like effects of GABAergic compounds, without producing any effects in the LAT and EPM (Rodríguez-Landa et al., 2013).

Ovarian Cycle Phase

Oestrous cyclicity was monitored daily (10:00 A.M.) through vaginal lavages and using light microscopy, as described in previous studies (Guillén-Ruiz et al., 2021; Rodríguez-Landa et al., 2021). Only females with three consecutive 4-day oestrous cycles (i.e., proestrus, oestrus, metestrus, and dioestrus) were included in the study and randomised to treatments. This criterion was used such that rats would be in vaginal proestrus or dioestrus on the day of behavioural evaluation.

Proestrus was chosen considering that this phase corresponds with higher levels of oestradiol and moderate levels of progesterone, while dioestrus was associated with lower levels of oestradiol and progesterone (Walmer et al., 1992; Goldman et al., 2007). The proestrus and dioestrus endocrine milieu have been consistently reported to lead rats to experience lower and higher levels of anxiety throughout the cycle (Estrada-Camarena et al., 2019; Rodríguez-Landa et al., 2021), which is in agreement with the objectives of the present study.

Stereotactic Surgery

The rats were pre-treated with atropine sulphate (0.05 mg/kg, i.p., Sigma-Aldrich, St. Louis, MO, United States) and then deeply anaesthetised with sodium pentobarbital (80 mg/kg, i.p., Cheminova, Ciudad de México, México). Additionally, local analgesia was induced in the surgical area (lidocaine 0.5% spray, PiSA-Farmaética, Guadalara, Jal, Mexico). They were fixed in a stereotaxic frame (Stoelting, Wood Dale, IL, United States), and a stainless-steel guide cannula (10-mm length, 22 gauge) was unilaterally implanted in the left dorsal hippocampus (anterior/posterior, −3.8 mm; medial/lateral, −2.0 mm; dorsal/ventral, −2.0 mm) according to the Paxinos and Watson (2014) rat brain atlas. To minimise postsurgical pain, 50 mg/kg metamizole (Dipirona50, Virbac Animal Health, Guadalajara, Mexico) was intramuscularly administered 4 days post-surgery. The treatments and behavioural tests began 7 days after surgery.

Microinjection

Chrysin, allopregnanolone or vehicle was microinjected in the dorsal hippocampus through a stainless-steel injector cannula (11-mm length, 30 gauge) connected by a polyethylene tube to a Hamilton microsyringe (10 μL) that was attached to a programmable infusion pump (KD Scientific, Holliston, MA, United States) that allowed controlled microinjection of 0.3 μL at a constant rate of 0.06 μL/min according to previous studies (Rodríguez-Landa et al., 2009). The microinjection lasted for 5 min. The injector cannula was left in place for an additional 5 min to allow diffusion and to avoid reflux.

To verify the microinjection site, at the end of the experiment, the rats were deeply anaesthetised with pentobarbital (80 mg/kg, i.p.). The guide cannula was microinjected 0.3 μL of Evans blue to mark the injection site, and then the brain was removed and immersed in 40% formaldehyde for 72 h to be sliced. The microinjection site was examined using a light microscope, and the Paxinos and Watson rat brain atlas was used as a reference.

Behavioural Tests

The behavioural tests began 5 min after the drug microinjections were completed. The effects of the treatments on anxiety-like behaviour were first evaluated in the EPM (evaluated variables: time spent on the open arms, number of open-arm entries and number of closed-arm entries; 5-min session), and then in the LAT (evaluated variables: number of crossings, time spent grooming and time spent rearing; 5-min session) to discard motor effects, as described in Supplementary Material 1. All sessions were videotaped. Two blinded independent observers measured the variables using the ex Professional software program until > 95% agreement was reached among them.

Statistical Analysis

The data were analyzed using the two-way analysis of variance (ANOVA), with treatment and the oestrous cycle phase as
FIGURE 1 | Timeline of experimental interventions in oestrous cycling rats. Effect of chrysin (Chry) and allopregnanolone (Allo) in proestrus or dioestrus females. Fourteen groups were included (n = 8 rats per group). Chrysin and allopregnanolone were administered at 0.25, 0.5, and 1 µg (A). Effect of GABA<sub>A</sub>/benzodiazepine receptor complex antagonists on actions of Chry and Allo in proestrus or dioestrus females (B). Twelve antagonised groups were included with data of VEH, Chry and Allo at *proestrus and **dioestrus from (A). VEH, vehicle; Picr, picrotoxin; Bic, bicuculline; Flu, flumazenil; EPM, elevated plus maze; LAT, locomotor activity test.

factors once the assumptions of normality and homogeneity were verified. The level of significance was set at p < 0.05. Values of p ≤ 0.05, as determined by ANOVA, were followed by the Student-Newman-Keuls post hoc test. The results are expressed as mean ± standard error. All analyses were conducted using SigmaPlot (version 12.0; Systat Software, Chicago, IL, United States).

RESULTS

Verification of the Microinjection Site
Six rats were excluded from the statistical analysis. Three rats removed the implants before the experiment concluded, and three rats were incorrectly implanted and presented areas of oedema and hemorrhage that surrounded the microinjection site. The brain analysis of the remaining rats confirmed that the microinjection effectively targeted the dorsal hippocampus at the intended stereotactic coordinates approximately in anterior/posterior, −3.48 to −4.20 mm from bregma; medial/lateral, −2.0 mm; dorsal/ventral, −2.0 to −2.5 mm as illustrated in Supplementary Figure 1. Thus, the final data analysis included seven to eight rats per group.

Effects of Chrysin on Anxiety-Like Behaviour

Elevated Plus Maze
The analysis of the time spent on the open arms revealed significant effects of the treatment \( F_{(6,96)} = 37.647, p < 0.001 \) and oestrous cycle phase \( F_{(1,96)} = 13.017, p < 0.001 \) and a significant treatment × oestrous cycle phase interaction \( F_{(6,96)} = 73.649, p < 0.001 \). The post hoc test showed that the vehicle-dioestrus group exhibited significantly less time in the open arms compared with the vehicle-proestrus group. In proestrus, 0.5 and 1 µg of chrysin and allopregnanolone reduced this variable compared with the vehicle group and 0.25 µg of chrysin and allopregnanolone groups, reaching similar values as the vehicle-dioestrus group. No significant differences were found between 0.5 and 1 µg of chrysin and allopregnanolone during proestrus. In dioestrus, only 0.5 µg of chrysin and allopregnanolone significantly increased the time...
spent on the open arms compared with the vehicle-dioestrus group and 0.25 and 1 µg of chrysin and allopregnanolone groups (Figure 2A). The microinjection of 0.25 and 1 µg of chrysin and allopregnanolone did not significantly affect this variable.

The analysis of the number of entries into the open arms showed no significant effect of the treatment \( F(6,96) = 12.050, p = 0.183 \) but a significant effect of the oestrous cycle phase \( F(1,96) = 5.425, p = 0.022 \) and a significant treatment \( \times \) oestrous cycle phase interaction \( F(6,96) = 14.267, p < 0.001 \). The post hoc test showed that the vehicle-dioestrus group exhibited a significantly lower number of entries into the open arms than the vehicle-proestrus group. In proestrus, chrysin (0.5 µg) and allopregnanolone (1 µg) equally reduced the number of entries into the open arms compared with the vehicle group and 0.25 µg of chrysin and allopregnanolone groups, reaching similar values as the vehicle-dioestrus group. In dioestrus, only 0.5 µg of chrysin and allopregnanolone increased the number of entries into the open arms compared with the vehicle-dioestrus group and 0.25 and 1 µg of chrysin and allopregnanolone groups (Figure 2B). The microinjection of 0.25 and 1 µg of chrysin and allopregnanolone did not affect this variable in dioestrus.

The results of the closed-arm entries are presented in Supplementary Table 1. The statistical analysis did not reveal significant differences associated with treatments \( F(6,96) = 0.475, p = 0.826 \), the ovarian cycle phase \( F(1,96) = 0.350, p = 0.556 \), and the treatment \( \times \) oestrous cycle phase interaction \( F(6,96) = 1.927, p = 0.084 \).

**Locomotor Activity Test**

The LAT results are presented in Supplementary Table 2. None of the variables in this test (i.e., crossings, grooming, and rearing) were significantly affected by the treatments or ovarian cycle phase.

**INFLUENCE OF GABA\textsubscript{A} ANTAGONISTS ON CHRYSIN-INDUCED ANXIOLYTIC ACTIVITY**

**Elevated Plus Maze**

The analysis of the time spent on the open arms revealed significant effects of the treatment \( F(8,121) = 8.104, p < 0.001 \) and the oestrous cycle phase \( F(1,121) = 106.512, p < 0.001 \) and a significant treatment \( \times \) oestrous cycle phase interaction \( F(8,121) = 7.892, p < 0.001 \). The post hoc test showed that the administration of picrotoxin, bicuculline, and flumazenil blocked the decrease in the time spent on the open arms that was produced by 0.5 µg of chrysin and allopregnanolone in proestrus, reaching values that were similar to those in the vehicle-proestrus group. Picrotoxin, bicuculline, and flumazenil prevented the increase in the time spent on the open arms that was produced by 0.5 µg of chrysin and allopregnanolone in dioestrus, reaching values that were similar to those in the vehicle-dioestrus group (Figure 3A). No significant differences were detected between the effects of the three antagonists on this variable.

The analysis of the number of entries into the open arms showed no effect of treatment \( F(8,121) = 1.450, p = 0.183 \) but a significant effect of the oestrous cycle phase \( F(1,121) = 81.488, p < 0.001 \) and a significant treatment \( \times \) oestrous cycle phase interaction \( F(8,121) = 14.508, p < 0.001 \). The post hoc test showed that the administration of the three antagonists in proestrus blocked the effect of 0.5 µg of chrysin and allopregnanolone on the number of entries into the open arms, producing values that were similar to those in the vehicle-proestrus group. In dioestrus, the three antagonists blocked the increase in the number of entries into the open arms that was produced by 0.5 µg of chrysin and allopregnanolone, producing values that were similar to those in the vehicle-dioestrus group (Figure 3B). No significant differences were detected between the effects of the different antagonists on this variable.

The results of the closed-arm entries are presented in Supplementary Table 3. The statistical analysis did not reveal significant differences associated with treatments \( F(8,121) = 0.949, p = 0.479 \), the ovarian cycle phase \( F(1,121) = 2.902, p = 0.097 \) and the treatment \( \times \) oestrous cycle phase interaction \( F(8,121) = 0.883, p = 0.433 \).

**DISCUSSION**

The present study explored the effects of the dorsal hippocampus in chrysin and allopregnanolone on anxiety-like behaviour associated with low (dioestrus phase) and high (proestrus phase) concentrations of ovarian hormones and the involvement of the GABA\textsubscript{A}/benzodiazepine receptor complex in such effects. Thus, this is the first report to show that chrysin, similar to allopregnanolone, regulates anxiety-like behaviour by targeting a brain structure involved in the physiopathology of anxiety (i.e., the hippocampus), which depends on the endocrine state associated with the ovarian cycle. This study contributes to the delineation of the neuroanatomical substrate involved in the anxiolytic-like effects of the flavonoid chrysin.

The EPM is a widely validated unconditioned model of anxiety that is used to study the potential anxiogenic and anxiolytic effects of drugs, their mechanisms of action and their brain targets. In this model, higher anxiety-like behaviour was observed when rats spent less time in the open arms, whereas lower anxiety-like behaviour was observed when rats spent more time in the open arms (Korte and de Boer, 2003). Interestingly, rats are treated with specific doses of anxiolytic drugs that activate the GABAergic system and spend more time in the open arms of the EPM without showing changes in their general locomotor activity (Rodgers et al., 1997). In the present study, 0.25 µg of chrysin and allopregnanolone did not modify the levels of anxiety that were observed in rats in dioestrus and oestrus. Increases in the number of entries into the open arms and time spent on the open arms were brought about by the microinjection of 0.5 µg of chrysin and allopregnanolone in the dorsal hippocampus in dioestrus rats.
This behavioural change suggests an anxiolytic-like effect that is similar to that of anxiolytic drugs such as benzodiazepines and their derivatives (Rezvanfard et al., 2009; Ravenelle et al., 2018; Rombolà et al., 2019, 2020).

The anxiolytic effects of chrysin and allopregnanolone in dioestrus rats resemble anxiolysis, which naturally occurs in proestrus. In contrast, microinjections of 0.5 and 1 µg of chrysin and allopregnanolone in proestrus rats blocked the naturally occurring anxiolysis associated with this ovarian cycle phase. These results suggest a switch in the effects of chrysin and allopregnanolone when relatively high doses were microinjected into the dorsal hippocampus; however, they were not associated with sedative or stimulant effects on locomotor activity. One possible explanation for these findings in the EPM is the high plasticity of the GABA\textsubscript{A}/benzodiazepine receptor complex in the presence of these ligands. In vitro studies have shown that high concentrations of GABAergic agonists may alter the GABA\textsubscript{A} subunit configuration to elicit desensitization and even lead to the inactivation of this receptor subtype (Mathers, 1991; Krall et al., 2015). Both chrysin and allopregnanolone target GABA\textsubscript{A} receptors, and steroid hormone concentrations are high in proestrus (MacKenzie and Maguire, 2014). Thus, the combination of high concentrations of endogenous and exogenous ligands (i.e., chrysin plus endogenous steroids or allopregnanolone plus endogenous steroids) may reduce GABA\textsubscript{A} receptor sensitivity, interfere with naturally occurring proestrus-dependent anxiolysis and block the facilitation of GABA\textsubscript{A}-mediated inhibition by exogenous ligands.

The effect of the highest dose of chrysin or allopregnanolone (1 µg) microinjected into the dorsal hippocampus of dioestrus rats supports the hypothesis of the lower sensitivity of the GABA\textsubscript{A} receptor, showing an inverted-U effect and returning anxiety to
Figure 3 | Influence of GABA<sub>A</sub> receptor antagonists on the effects of microinjections of chrysin and allopregnanolone in the dorsal hippocampus in the elevated plus maze in rats. (A) Time spent on open arms. (B) Number of entries into open arms. * <i>p</i> < 0.05, vs. VEH and antagonists plus C0.5 and A0.5 in proestrus; † <i>p</i> < 0.05, vs. VEH in proestrus; ‡ <i>p</i> < 0.05, vs. VEH and antagonists plus C0.5 and A0.5 plus in dioestrus (Student-Newman-Keuls post hoc test). VEH, vehicle; C0.5, 0.5 µg chrysin; P, picrotoxin; B, bicuculline; F, flumazenil; A0.5, 0.5 µg allopregnanolone. The data are expressed as the mean ± standard error of the mean from 7 to 8 rats per group.
depending on the endocrine state of females. Higher doses of chrysin, which may induce adverse effects, remain unexplored. Further research should be conducted to evaluate the potential negative or toxic effects.

To avoid false positives or false negatives in anxiety models, possible non-specific motor effects of drugs or surgical manipulations need to be discarded. Closed-arm entries were introduced as a measure of motor activity in the EPM (Rodgers and Johnson, 1995). However, agreement as to the “pure” indicator of locomotor activity index of this variables in the EPM remains ambiguous because it is considered more as an index of protected exploration (Bourin, 2015). Recent studies have included the LAT as a complementary measure of a purer locomotor activity to either discard or identify motor changes associated with experimental manipulations (Rodríguez-Landa et al., 2009; Hernández-López et al., 2017). In the present study, none of the treatments affected the closed-arm entries in the EPM or the motor activity in the LAT (i.e., crossings, rearing, and grooming), thus demonstrating the specificity of anxiolytic-like effects in dioestrus and anxiogenic-like effects in proestrus when chrysin and allopregnanolone were microinjected into the hippocampus. These effects are consistent with those in previous studies that reported no significant effects of anxiolytic drugs, the ovarian cycle, or stereotactic surgery on locomotor activity (Rodríguez-Landa et al., 2009, 2013, 2019; Carro-Juárez et al., 2012; Hernández-López et al., 2017; García-Ríos et al., 2019). On the other hand, intraperitoneal injections of chrysin (2 mg/kg) in dioestrus rats increased grooming behaviour in the LAT (Rodríguez-Landa et al., 2021). This difference with the present study could be associated with the different routes of administration and specific experimental conditions, suggesting that the dorsal hippocampus does not directly participate in the regulation of grooming behaviour elicited by chrysin.

The present findings support the hypothesis that chrysin interacts with the GABAergic system in the dorsal hippocampus, which highly expresses GABA_A receptors and participates in the regulation of emotional processing, anxiety and neuropharmacological effects of anxiolytic drugs (Farajdokht et al., 2020). Studies have explored the participation of the GABA_A/benzodiazepine receptor complex in the actions of anxiolytic drugs using specific antagonists. Picrotoxin is a non-competitive GABA_A receptor antagonist that blocks the flux of chloride ions through the receptor channel, decreasing GABAergic function (Olsen, 2006). Through this mechanism, picrotoxin blocks the effects of drugs, such as diazepam, gabapentin and allopregnanolone (Kumar and Goyal, 2007; Kumar et al., 2009; Carro-Juárez et al., 2012). Bicuculline is a competitive antagonist of the gamma-aminobutyric acid recognition site in the GABA_A receptor. It blocks the activation of this receptor by flavonoids and neurosteroids (Cueto-Ecobedo et al., 2020). Flumazenil is a selective antagonist of the benzodiazepine recognition site of the GABA_A receptor and interferes with the anxiolytic effects of benzodiazepines and allopregnanolone (Fernández-Guasti and Picazo, 1995; Farajdokht et al., 2020). In the present study, the systemic administration of picrotoxin, bicuculline, and flumazenil completely prevented the anxiolytic-like effects of microinjections of 0.5 µg of chrysin and allopregnanolone in the dorsal hippocampus in dioestrus rats, underscoring the critical role of the GABA_A/benzodiazepine receptor complex in anxiolysis mediated by both drugs. Additionally, all GABAergic antagonists elicited a partial reversal of the anxiogenic-like effect of chrysin and allopregnanolone, which was observed in proestrus rats. Such effects may be explained by the saturation of the GABA_A receptor by its ligands, leading to changes in its functionality. The present results suggest that other endogenous substances that are associated with the endocrine milieu during proestrus may directly impact the effects of chrysin and allopregnanolone on GABA_A receptor function. Altogether, these findings indicate that the GABA_A/benzodiazepine receptor complex in the dorsal hippocampus participates in the neuropharmacological effects of chrysin and allopregnanolone on anxiety-like behaviour in female rats. The present findings should prompt further clinical research on chrysin, similar to the neurosteroid allopregnanolone, on its ability to ameliorate neuropsychiatric symptoms in women with low concentrations of steroid hormones (Paul et al., 2020; Pinna, 2020a,b).

The present study had several limitations. The groups in Experiment 2 were combined with groups that received microinjections of a vehicle and 0.5 µg of chrysin and allopregnanolone from Experiment 1. This decision was based on the 3R principles (Russell et al., 2005) to reduce the number of experimental animals. The statistical results validated this decision because between-group comparisons yielded significant differences (p < 0.05, p < 0.001), providing satisfactory statistical support for the neurobehavioural findings. Supporting this decision, we used antagonist doses previously reported in the literature by our laboratory group to avoid replicated groups. Such doses lack effects per se in the EPM and LAT (Rodríguez-Landa et al., 2013, 2019). Furthermore, future studies could be conducted to evaluate the microinjection of GABAergic antagonists in the hippocampus to identify possible local interactions among the GABA_A/benzodiazepine receptor complex, chrysin, or allopregnanolone. Finally, another potential limitation could be the use of unilateral vs. bilateral implants into the dorsal hippocampus, which was decided to avoid a potentially higher lesion in the brain, considering the dimensions of the implanted guide cannula. In support of our design, previous studies have reported anxiolytic- and antidepressant-like effects after the unilateral microinjection of substance P (Carvalho et al., 2008), progesterone (Estrada-Camarena et al., 2002), and allopregnanolone (Rodríguez-Landa et al., 2005, 2009), with no significant differences between the hippocampus side. In the present study, we microinjected chrysin and allopregnanolone into the left (dorsal hippocampus) hemisphere to observe clear anxiolytic-like effects.

**CONCLUSION**

The results of this study confirm that chrysin affects anxiety-like behaviour in females and that it directly affects the dorsal hippocampus, a structure with a key role in affective and emotional behaviour modulation. GABA_A receptors in the dorsal
hippocampus seem to have different degrees of participation in the effects of chrysin on anxiety, which is modulated by the endocrine milieu in females, similar to allopregnanolone. Specifically, hormone conditions in dioestrus favor the anxiolysis elicited by chrysin, in interaction with the different binding sites of GABA<sub>A</sub> receptors. In contrast, the prooestrus endocrine milieu leads to anxiogenic effects of this flavonoid, which are partially mediated by the GABA<sub>A</sub>/benzodiazepine receptor complex. Altogether, our findings contribute to the knowledge of the neuroanatomical and neuropharmacological bases of the effects of chrysin on anxiety-like behaviour that are associated with hormonal fluctuations during the ovarian cycle phases.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The animal study was reviewed and approved by the Internal Committee for the Care and Use of Laboratory Animals (CICUAL-UV).

**REFERENCES**

Albrecht, A., Redavide, E., Reges-Tiur, S., Stork, O., and Richter-Levin, G. (2021). Hippocampal GABAergic interneurons and their co-localized neuropeptides in stress vulnerability and resilience. Neurosci. Biobehav. Rev. 122, 229–244. doi: 10.1016/j.neubiorev.2020.11.002

Bitran, D., Hilvers, R. J., and Kellogg, C. K. (1991). Anxiolytic effects of 3 alpha-hydroxy-5 alpha[beta]-pregn-20-one: endogenous metabolites of progesterone that are active at the GABA<sub>A</sub> receptor. Brain Res. 561, 157–161. doi: 10.1016/0006-8993(91)90761-j

Bosse, R., and Di Paolo, T. (1996). The modulation of brain dopamine and GABA<sub>A</sub> receptors by estradiol: a clue for CNS changes occurring at menopause. Cell. Mol. Neurobiol. 16, 199–212. doi: 10.1007/bf02088176

Bourin, M. (2015). Animal models for screening anxiolytic-like drugs: a perspective. Dial. Clin. Neurosci. 17, 295–303. doi: 10.31887/DCNS.2015.17.3/mbourin

Carro-Juárez, M., Rodríguez-Landa, J. F., Rodríguez-Peña, M. L., Rovirosa-Hernández, M. J., and García-Orduña, F. (2012). The aqueous crude extract of Montanoa frutescens produces anxiolytic-like effects similarly to diazepam in Wistar rats: involvement of GABA<sub>A</sub> receptor. J. Ethnopharmacol. 143, 592–598. doi: 10.1016/j.jep.2012.07.022

Carvalho, M. C., Masson, S., Brandão, M. L., and de Souza Silva, M. A. (2008). Anxiolytic-like effects of substance P administration into the dorsal, but not ventral, hippocampus and its influence on serotonin. Peptides 29, 1191–1200. doi: 10.1016/j.peptides.2008.02.014

Crocetti, L., and Guerrini, G. (2020). GABA<sub>A</sub> receptor subtype modulators in medicinal chemistry: an updated patent review (2014-present). Expert. Opin. Ther. Pat. 30, 409–432. doi: 10.1080/13543776.2020.1746764

Cueto-Ecobedo, J., Andrade-Soto, J., Lima-Maximino, M., Maximino, C., Hernández-López, F., and Rodríguez-Landa, J. F. (2020). Involvement of GABA<sub>A</sub>ergic system in the antidepressant-like effects of chrysin (5,7-dihydroxyflavone) in ovariectomized rats in the forced swim test: comparison with neurosteroids. Behav. Brain Res. 386:112590. doi: 10.1016/j.bbr.2020.112590

Engin, E., and Treit, D. (2007a). The anxiolytic-like effects of allopregnanolone of GABA<sub>A</sub> and 5-HT<sub>1A</sub> receptors in the rafe nuclei and hippocampus. *Peptides* 29, 1191–1200. doi: 10.1016/j.peptides.2008.02.014

Funding

This study was part of SIREI project no. DGI: 26650201961 to JFR-L. This research was partially funded by SEP-PROMEP (Grant No. 103.5/05/1955, UVER-PTC-155), Programa de Fortalecimiento Académico del Posgrado de Alta Calidad (Grant No. 1010/458/2013, C-703/2013), and Sistema Nacional de Investigadores: Exp. 32753 (JFR-L), 19191 (LM-M), and 32935 (BB-M).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnbeh.2021.789557/full#supplementary-material

**AUTHOR CONTRIBUTIONS**

JFR-L, DS, and FH-L: conceptualisation and methodology. FH-L, LM-M, and ER-D: methodology and formal analysis. JFR-L, BB-M, and DS: data curation. JFR-L, LM-M, and DS: writing manuscript. All authors reviewed, discussed, and approved the final version of the manuscript.

**FUNDING**

This study was part of SIREI project no. DGI: 26650201961 to JFR-L. This research was partially funded by SEP-PROMEP (Grant No. 103.5/05/1955, UVER-PTC-155), Programa de Fortalecimiento Académico del Posgrado de Alta Calidad (Grant No. 1010/458/2013, C-703/2013), and Sistema Nacional de Investigadores: Exp. 32753 (JFR-L), 19191 (LM-M), and 32935 (BB-M).
Goldman, J. M., Murr, A. S., and Cooper, R. L. (2007). The rodent estrous cycle: characterization of vaginal cytology and its utility in toxicological studies. Birth Defects Res. B, Dev. Reprod. Toxicol. 80, 84–97. doi: 10.1002/bdrb.20106

Guillén-Ruiz, G., Cueto-Escobedo, J., Hernández-López, F., Rivera-Aburto, L. E., Herrera-Huerta, E. V., and Rodríguez-Landa, J. F. (2021). Estrus cycle modulates the anxiogenic effects of caffeine in the elevated plus maze and light/dark box in female rats. Behav. Brain Res. 413:113469. doi: 10.1016/j.bbr.2021.113469

Hernández-López, F., Rodríguez-Landa, J. F., Puga-Olguín, A., Germán-Ponciano, L. J., Rivadeneyra-Domínguez, E., and Bernal-Morales, B. (2017). Analysis of activity and motor coordination in rats undergoing stereotactic surgery and implantation of a cannula into the dorsal hippocampus. Neurotox Res. 32, 579–586. doi: 10.1556/ntr.2016.03.004

Jimenez, J. C., Su, K., Goldberg, A. R., Luna, V. M., Biane, J. S., Ordekh, G., et al. (2018). Anxiety cells in a hippocampal-hypothalamic circuit. Neuron 97, 670–683. doi: 10.1016/j.neuron.2018.01.016

Korte, S. M., and de Boer, S. F. (2003). A robust animal model of state anxiety: fear- potentiated behaviour in the elevated plus-maze. Eur. J. Pharmacol. 463, 163–175. doi: 10.1016/s0014-2999(03)01279-2

Krall, J., Balle, T., Krosgaard-Larsen, N., Sørensen, T. E., and Krosgaard-Larsen, P. (2015). GABAA receptor partial agonists and antagonists: structure, binding mode, and pharmacology. Adv. Pharmacol. 72, 201–227. doi: 10.1016/bs.apha.2014.10.003

Kumar, A., and Goyal, R. (2007). Possible involvement of GABAergic modulation in the protective effect of gabapentin against immobilization stress-induced behavior alterations and oxidative damage in mice. Fundam. Clin. Pharmacol. 21, 575–581. doi: 10.1111/j.1472-8206.2007.00524.x

Kumar, A., Goyal, R., and Prakash, A. (2009). Possible GABAergic mechanism in the protective effect of allopregnanolone against immobilization stress. Eur. J. Pharmacol. 602, 343–347. doi: 10.1016/j.ejpha.2008.11.038

Lovick, T. A. (2008). GABA in the female brain: oestrous cycle-related changes in GABAergic function in the periaqueductal grey matter. Pharmacol. Biochem. Behav. 90, 43–50. doi: 10.1016/j.pbb.2007.12.014

MacKenzie, G., and Maguire, J. (2014). The role of ovarian hormone-derived neurosteroids on the regulation of GABA receptors in anxiety disorders. Psychopharmacology 231, 3333–3342. doi: 10.1007/s00213-013-3423-z

Marcondes, F. K., Miguel, K. J., Melo, L. L., and Spadari-Bratfisch, R. C. (2001). Estrous cycle influences the response of female rats in the elevated plus-maze test. Physiol. Behav. 74, 435–440. doi: 10.1016/s0031-9384(01)00593-5

Martin-García, E., and Pallarés, M. (2005). Intrahippocampal nicotine and neurosteroids effects on the anxiety-like behaviour in voluntary and chronic alcohol-drinking rats. Behav. Brain Res. 164, 117–127. doi: 10.1016/j.bbr.2005.06.007

Mathers, D. A. (1991). Activation and inactivation of the GABA receptor: insights from comparison of native and recombinant subunit assemblies. Can. J. Pharmacol. Toxicol. 69, 1057–1063. doi: 10.1139/91j-157

Mödol, L., Darbra, S., and Pallarés, M. (2011). Neurosteroids infusion into the CA1 hippocampal region on exploration, anxiety-like behaviour and aversive learning. Behav. Brain Res. 222, 223–229. doi: 10.1016/j.bbr.2011.03.058

National Research Council (2011). Guide for the Care and Use of Laboratory Animals. Washington: National Academy Press.

Nin, M. S., Salles, F. B., Azeredo, L. A., Frazon, A. P., Gomez, R., and Barros, H. M. (2008). Antidepressant effect and changes of GABA receptor gamma2 subunit mRNA after hippocampal administration of allopregnanolone in rats. J. Psychopharmacol. 22, 477–485. doi: 10.1177/026988110781525

NOM-001-2004-SSA1 (2004). National Regulations for the Protection and Care of Laboratory Animals. Mexico: Secretaría de Salud.

Olsen, R. W. (2006). Picrotoxin-like channel blockers of GABA receptors. Proc. Natl. Acad. Sci. USA 103, 6081–6082. doi: 10.1073/pnas.0601124103

Pacheco-M., Pinna, G., and Guidotti, A. (2020). Allopregnanolone: from molecular pathophysiology to therapeutics. a historical perspective. Neurobiol. Stress 12:000215. doi: 10.1016/j.jnstr.2020.100215

Paxinos, G., and Watson, C. (2014). The Rat Brain in Stereotaxic Coordinates. San Diego, CA: Elsevier Academic Press.
Rombolà, L., Scuteri, D., Watanabe, C., Sakurada, S., Hamamura, K., Sakurada, et al. (2020). Role of 5-HT₁A receptor in the anxiolytic-relaxant effects of bergamot essential oil in rodent. *Int. J. Mol. Sci.* 21:2597. doi: 10.3390/ijms21072597

Russell, W. M. S., Burch, R. L., and Hume, C. W. (2005). *The Principles of Humane Experimental Technique*. Baltimore: Johns Hopkins Bloomberg School of Public Health.

Salgueiro, J. B., Ardenghi, P., Dias, M., Ferreira, M. B., Izquierdo, I., and Medina, J. H. (1997). Anxiolytic natural and synthetic flavonoid ligands of the central benzodiazepine receptor have no effect on memory tasks in rats. *Pharmacol. Biochem. Behav.* 58, 887–891. doi: 10.1016/s0091-3057(97)00054-3

Stanikova, D., Luck, T., Pabst, A., Bae, Y. J., Hinz, A., Glaser, H., et al. (2019). Associations between anxiety, body mass index, and sex hormones in women. *Front. Psychiatry* 10:479. doi: 10.3389/fpsyg.2019.00479

Velasco, E. R., Florido, A., Milad, M. R., and Andero, R. (2019). Sex differences in fear extinction. *Neurosci. Biobehav. Rev.* 103, 81–108. doi: 10.1016/j.neubiorev.2019.05.020

Walmer, D. K., Wrona, M. A., Hughes, C. L., and Nelson, K. G. (1992). Lactoferrin expression in the mouse reproductive tract during the natural estrous cycle: correlation with circulating estradiol and progesterone. *Endocrinology* 131, 1458–1466. doi: 10.1210/endo.131.3.1305477

Wilson, M. A. (1992). Influences of gender, gonadectomy, and estrous cycle on GABA/BZ receptors and benzodiazepine responses in rats. *Brain Res. Bull.* 29, 165–172. doi: 10.1016/0361-9230(92)90022-p

Zanoli, P., Avallone, R., and Baraldi, M. (2000). Behavioral characterization of the flavonoids apigenin and chrysin. *Fitoterapia* 1, S117–S123. doi: 10.1016/s0367-326x(00)00186-6

Zhang, W. N., Bast, T., Xu, Y., and Feldon, J. (2014). Temporary inhibition of dorsal or ventral hippocampus by muscimol: distinct effects on measures of innate anxiety on the elevated plus maze, but similar disruption of contextual fear conditioning. *Behav. Brain Res.* 262, 47–56. doi: 10.1016/j.bbr.2013.10.044

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Rodríguez-Landa, Hernández-López, Martinez-Mota, Scuteri, Bernal-Morales and Rivadeneyra-Dominguez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.